Cell foundry with high product specificity and catalytic activity for 21-deoxycortisol biotransformation

BACKGROUND: 21-deoxycortisol (21-DF) is the key intermediate to manufacture pharmaceutical glucocorticoids. Recently, a Japan patent has realized 21-DF production via biotransformation of 17-hydroxyprogesterone (17-OHP) by purified steroid 11β-hydroxylase CYP11B1. Due to the less costs on enzyme iso...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Shuting, Wang, Ying, Yao, Mingdong, Liu, Hong, Zhou, Xiao, Xiao, Wenhai, Yuan, Yingjin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470312/
https://www.ncbi.nlm.nih.gov/pubmed/28610588
http://dx.doi.org/10.1186/s12934-017-0720-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470312/
https://www.ncbi.nlm.nih.gov/pubmed/28610588
http://dx.doi.org/10.1186/s12934-017-0720-y

Ejemplares similares